Mesoblast Limited Sponsored ADR (MESO)
Summary
Mesoblast Limited (MESO) Q4 2026 Earnings Call Transcript
Mesoblast Limited (MESO) Q4 2026 Earnings Call Transcript
Mesoblast H2 Earnings Call Highlights
Mesoblast NASDAQ: MESO reported $115 million in net revenue for fiscal 2026, its first full year of commercial sales for RYONCIL, the company's FDA-approved allogeneic mesenchymal stromal cell therapy for children with steroid-refractory acute graft-versus-host disease, or GVHD.
MESO Completes Patient Treatment in Chronic Back Pain Study, Stock Up
Mesoblast rises after completing treatment of 350 patients in a pivotal phase III study of rexlemestrocel-L for treating chronic low back pain.
Mesoblast Limited Sponsored ADR Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| NA Nizar Araji National Bank Of Canada /FI/ | 700 | $5,066.25 | $11,158 | $6,091.75 | 120.24% |
| YA Yinka Akinsola Blue Trust Inc. | 1,002 | $15,410.76 | $17,324.58 | $1,913.82 | 12.42% |
| FFA Fi3 FINANCIAL ADVISORS LLC Fi3 FINANCIAL ADVISORS LLC | 7,891 | $136,352.7 | $136,435.39 | $82.69 | 0.06% |
 Dinan Hu R Squared Ltd | 14,492 | $222,886.96 | $250,566.68 | $27,679.72 | 12.42% |
 Li Peng China Universal Asset Management Co. Ltd. | 8,319 | $138,131.5 | $117,880.23 | -$20,251.27 | -14.66% |
Mesoblast Limited Sponsored ADR Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Edward Tenthoff Piper Sandler | 1,207.75 | $21,956.95 | $20,882.05 | -$1,074.9 | -4.9% |
Mesoblast Limited Sponsored ADR (MESO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Mesoblast Limited Sponsored ADR ever had a stock split?
Mesoblast Limited Sponsored ADR Profile
| Biotechnology Industry | Healthcare Sector | Silviu Itescu CEO | NASDAQ (NGS) Exchange | 590717401 CUSIP |
| AU Country | 108 Employees | - Last Dividend | 10 Jan 2024 Last Split | 13 Nov 2015 IPO Date |
Overview
Mesoblast Limited is a biotechnology company focused on developing innovative regenerative medicine products, operating in Australia, the United States, Singapore, and Switzerland. It specializes in creating therapies in various fields such as cardiovascular diseases, spine orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory diseases. At the core of Mesoblast's research and development efforts is their proprietary technology platform that utilizes mesenchymal lineage cells. The company, founded in 2004 and headquartered in Melbourne, Australia, is committed to advancing the treatment of severe and life-threatening conditions through its regenerative medicine technologies. Mesoblast has established strategic partnerships with major pharmaceutical companies to expand and accelerate the delivery of its innovative treatments to patients globally.
Products and Services
- Remestemcel-L for Systemic Inflammatory Diseases
Currently in Phase III clinical trials, Remestemcel-L is being developed for the treatment of severe inflammatory conditions, including steroid refractory acute graft versus host disease (GVHD), acute respiratory distress syndrome (ARDS), and biologic refractory inflammatory bowel disease (IBD). This treatment utilizes mesenchymal lineage cells to mitigate inflammatory responses in affected patients.
- Remestemcel-L for Cardiovascular and Spine Orthopedic Disorders
In another application of Remestemcel-L, Phase III clinical trials are underway to assess its efficacy in treating chronic heart failure and chronic low back pain due to degenerative disc disease. By leveraging the regenerative capabilities of mesenchymal lineage cells, this treatment aims to restore function and reduce pain in patients suffering from these debilitating conditions.
- MPC-300-IV for Biologic Refractory Rheumatoid Arthritis and Diabetic Nephropathy
This product is under development for patients with biologic refractory rheumatoid arthritis and diabetic nephropathy. MPC-300-IV aims to provide a novel treatment option for these chronic inflammatory conditions by targeting inflammation and facilitating tissue regeneration.
- MPC-25-IC for Acute Myocardial Infarction
Designed for the treatment or prevention of acute myocardial infarction (heart attacks), MPC-25-IC is a targeted therapy that utilizes mesenchymal lineage cells to promote repair processes in the heart, potentially improving outcomes for heart attack patients.
Beyond its in-house development projects, Mesoblast has formed key strategic partnerships to extend its reach and impact. These collaborations include an alliance with Tasly Pharmaceutical Group for delivering therapies for heart failure and heart attacks in China, an agreement with JCR Pharmaceuticals Co. Ltd. for addressing wound healing in epidermolysis bullosa patients, and a partnership with Grünenthal for the development and commercialization of cell therapies aimed at treating chronic low back pain.
